|
|
|
| Application Value of 3.0T MR Dynamic Enhancement Combined with Serum PKM2 and CDCA5 Detection in Preoperative Assessment of Endometrial Carcinoma Staging and Lymph Node Metastasis |
| LIU Dandan, SUN Jian, WU Jian |
| Jiamusi Maternal and Child Health Hospital, Heilongjiang Province, Jiamusi 154002, China |
|
|
|
|
Abstract Objective: To preliminarily explore the application value of 3.0T MR dynamic enhancement combined with serum pyruvate kinase M2 (PKM2) and cell division cycle associated protein 5 (CDCA5) detection in preoperative assessment of endometrial carcinoma staging and lymph node metastasis. Method: A total of 175 patients suspected of endometrial carcinoma who were admitted to Jiamusi Maternal and Child Health Hospital from January 2020 to October 2021 were selected as the research subjects. All the patients received surgical treatment in our hospital, and underwent 3.0T MR dynamic enhancement scanning and serum PKM2 and CDCA5 detection preoperative. Taking the surgical pathological results as the "gold standard", the accuracy, specificity, sensitivity and positive detection rate of 3.0T MR dynamic enhancement scanning and serum PKM2 and CDCA5 in the diagnosis of endometrial carcinoma were compared. MR enhancement parameters and serum levels of PKM2 and CDCA5 in patients with different stages and lymph node metastasis were compared. Result: Postoperative pathological results showed that among 175 patients, 150 patients were diagnosed as endometrial carcinoma, including 82 cases in stage ⅠA, 42 cases in stage ⅠB, 21 cases in stage Ⅱ and 5 cases in stage Ⅲ. There were 5 cases with lymph node metastasis and 145 cases without lymph node metastasis. The sensitivity (96.00%) and accuracy (94.86%) of the combined diagnosis of endometrial carcinoma were higher than those of the 3.0T MR dynamic enhancement, PKM2, and CDCA5 single diagnosis (P<0.05). There was no significant difference in the specificity of various diagnostic methods (P>0.05). The positive detection rate in the combined diagnosis of stage ⅠA (96.34%) was higher than that in the 3.0T MR dynamic enhancement, PKM2, and CDCA5 single diagnosis (P<0.05). There were no significant differences in the positive detection rates of stage ⅠB, Ⅱ and Ⅲ among the various diagnostic methods (P>0.05). The maximal contrast enhanced rate (MCER), time to peak (TTP), PKM2, and CDCA5 in patients with different stages of endometrial carcinoma staging were compared, and stage Ⅲ >Ⅱ >ⅠB >ⅠA (P<0.05). The MCER, TTP, PKM2 and CDCA5 of endometrial carcinoma patients with lymph node metastasis were higher than those without lymph node metastasis (P<0.05). Conclusion: 3.0T MR dynamic enhancement combined with serum PKM2 and CDCA5 detection can improve the diagnostic rate of endometrial carcinoma, and provide reliable diagnostic reference for pathological progress such as different stages and lymph node metastasis.
|
|
Received: 23 September 2022
|
|
|
|
|
|
|
